Role of Advanced Glycation End Products in Hypertension and Atherosclerosis: Therapeutic Implications

被引:0
|
作者
Sudesh Vasdev
Vicki Gill
Pawan Singal
机构
[1] Memorial University of Newfoundland,Discipline of Medicine, Faculty of Medicine, Room H
[2] University of Manitoba,4310, Health Sciences Centre
来源
关键词
Hypertension; Atherosclerosis; Advanced glycation end products; Insulin resistance; Oxidative stress; Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
The vascular diseases, hypertension and atherosclerosis, affect millions of individuals worldwide, and account for a large number of deaths globally. A better understanding of the mechanism of these conditions will lead to more specific and effective therapies. Hypertension and atherosclerosis are both characterized by insulin resistance, and we suggest that this plays a major role in their etiology. The cause of insulin resistance is not known, but may be a result of a combination of genetic and lifestyle factors. In insulin resistance, alterations in glucose and lipid metabolism lead to the production of excess aldehydes including glyoxal and methylglyoxal. These aldehydes react non-enzymatically with free amino and sulfhydryl groups of amino acids of proteins to form stable conjugates called advanced glycation end products (AGEs). AGEs act directly, as well as via receptors to alter the function of many intra- and extracellular proteins including antioxidant and metabolic enzymes, calcium channels, lipoproteins, and transcriptional and structural proteins. This results in endothelial dysfunction, inflammation and oxidative stress. All these changes are characteristic of hypertension and atherosclerosis. Human and animal studies have demonstrated that increased AGEs are also associated with these conditions. A pathological role for AGEs is substantiated by studies showing that therapies that attenuate insulin resistance and/or lower AGEs, are effective in decreasing oxidative stress, lowering blood pressure, and attenuating atherosclerotic vascular changes. These interventions include lipoic acid and other antioxidants, AGE breakers or soluble receptors of AGEs, and aldehyde-binding agents like cysteine. Such therapies may offer alternative specific means to treat hypertension and atherosclerosis. An adjunct therapy may be to implement lifestyle changes such as weight reduction, regular exercise, smoking cessation, and increasing dietary intake of fruits and vegetables that also decrease insulin resistance as well as oxidative stress.
引用
收藏
页码:48 / 63
页数:15
相关论文
共 50 条
  • [31] The role of advanced glycation end products and their mechanism in DN
    李奕茜
    王洋
    方朝晖
    马建
    World Journal of Integrated Traditional and Western Medicine, 2017, 3 (03) : 8 - 11
  • [32] Role of advanced glycation end products in cellular signaling
    Ott, Christiane
    Jacobs, Kathleen
    Haucke, Elisa
    Santos, Anne Navarrete
    Grune, Tilman
    Simm, Andreas
    REDOX BIOLOGY, 2014, 2 : 411 - 429
  • [33] Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis
    Röcken, C
    Kientsch-Engel, R
    Mansfeld, S
    Stix, B
    Stubenrauch, K
    Weigle, B
    Bühling, F
    Schwan, M
    Saeger, W
    AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04): : 1213 - 1220
  • [34] Role of advanced glycation end products in diabetic neuropathy
    Sugimoto, Kazuhiro
    Yasujima, Minoru
    Yagihashi, Soroku
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) : 953 - 961
  • [35] The role of advanced glycation end products in human infertility
    Zhu, Jing-Ling
    Cai, Ya-qin
    Long, Shuang-lian
    Chen, Zhuo
    Mo, Zhong-cheng
    LIFE SCIENCES, 2020, 255
  • [36] Protein Advanced Glycation End Products and Their Implications in Pancreatic Cancer
    Senavirathna, Lakmini
    Pan, Sheng
    Chen, Ru
    CANCER PREVENTION RESEARCH, 2023, 16 (11) : 601 - 610
  • [37] Advanced Glycation End Products
    Thomas, Merlin C.
    DIABETES AND THE KIDNEY, 2011, 170 : 66 - 74
  • [38] Uncovering the role of circulating soluble receptor for advanced glycation end products in hypertension: relationships with albuminuria
    Tsioufis, C.
    Dimitriadis, K.
    Agelis, A.
    Poulakis, M.
    Selima, M.
    Kasiakogias, A.
    Miliou, A.
    Toutouzas, K.
    Stefanadis, C.
    EUROPEAN HEART JOURNAL, 2010, 31 : 249 - 249
  • [39] Uncovering the Role of Circulating Soluble Receptor for Advanced Glycation End Products in Hypertension: Relationships With Albuminuria
    Tsioufis, Costas
    Dimitriadis, Kyriakos
    Syrseloudis, Dimitris
    Thomopoulos, Costas
    Mazaraki, Anastasia
    Miliou, Antigoni
    Sideris, Skevos
    Stefanadi, Elli
    Tousoulis, Dimitris
    Stefanadis, Christodoulos
    CIRCULATION, 2009, 120 (18) : S1155 - S1155
  • [40] The Emerging Role of Circulating Soluble Receptor for Advanced Glycation End Products in Hypertension: Relationships with Albuminuria
    Tsioufis, C.
    Dimitriadis, K.
    Agelis, A.
    Poulakis, M.
    Kefala, A.
    Kasiakogias, A.
    Miliou, A.
    Toutouzas, K.
    Stefanadis, C.
    CIRCULATION, 2010, 122 (21)